Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN On-line: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2017020577
pages 507-514

Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers

Jun Du
Department of Pathology, Jinling Hospital, 305 ZhongShan East Road, 210002 Nanjing Jiangsu, China; Department of Pathology, South District of Anhui Provicinal Hospital, Hefei, 230036, China
Xiao-Jun Zhou
Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China; Department of Pathology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China


Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare malignant tumors. The mainstay of treatment patients with TET is surgical resection, and chemotherapy is necessary for patients with tumor invasion or metastasis who are unable to undergo complete radical excision. However, for those patients who are resistant to chemotherapy, targeted therapy has become the most popular tumor treatment program, as well as for thymic tumors. Many genes implicated in tumorigenesis and metastasis have also been reported to be therapeutic targets in thymic malignancies. A significant advance in TET treatment may derive from the identification of novel molecular biomarkers that can improve the diagnosis, prognosis, and treatment of tumors. We review a number of case reports and small clinical trials reporting that a few inhibitors, such as sorafenib and sunitinib, are effective in the treatment of thymoma. In this review, we describe the current potential drug targets and their roles in the development of thymic malignancy.

Articles with similar content:

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu
FLT3 Signaling and the Development of Inhibitors That Target FLT3 Kinase Activity
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Wallace Y. Langdon
miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 3
Muhammad Imran Qadir, Arooj Faheem
Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth